Flavonoid and experimental senolytic · Fact sheet
Fisetin
Also known as senolytic flavonoid · dietary fisetin
Fisetin is not an FDA-approved senolytic or anti-aging drug. Animal studies and early human mechanistic research justify clinical trials, but there is no proof that fisetin extends human life, reverses frailty, or prevents age-related disease.
What is Fisetin?
Fisetin is a flavonoid found in small amounts in foods such as strawberries and apples.
In geroscience it is studied as a senolytic—a compound intended to preferentially remove some senescent cells—but cell type, exposure, and model strongly affect that claim.
Benefits & claims
A prominent mouse study reported reduced senescence markers, improved health measures, and longer lifespan.
Human trials now examine vascular function, frailty, and treatment-related physical decline, but a trial design or biomarker shift is not a clinical benefit.
What the evidence supports
- Preclinical work supports a senolytic hypothesis and identified cell-type-specific effects.
- Early human research may clarify target engagement, but meaningful clinical outcomes remain unproven.
Research areas
- Cellular senescence
- Frailty
- Vascular function
- Physical function after cancer treatment
Dosage & frequency
No established human regimenFisetin senolytic schedules remain investigational. Trial-specific intermittent exposure is not an established longevity prescription.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
Formulation differences
- A food-associated flavonoid and a high-exposure trial product are different contexts.
Interactions & precautions
- Experimental senolytic schedules do not establish compatibility with anticoagulants, cancer medicines, or other high-exposure supplements.
What is still unresolved
- An effective human senolytic schedule and the long-term risk of repeated courses remain unresolved.
Side effects & risks
- A food constituent is not automatically safe at concentrated research exposure.
- Human adverse-event data are too limited to define uncommon, interaction, or long-term risks.
- Supplement identity, purity, and formulation may not match clinical-trial material.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Mostly animal or lab researchThe most influential healthspan and lifespan findings are from mice and cell systems. Human work is early, mechanistic, small, or still recruiting and does not establish better function, fewer diseases, or longer life.
Studies
Cell, tissue, and mouse evidence that motivated human senolytic research.
Small Phase 2 frailty trial record with no public outcomes result.
Mechanistic human study that does not establish longevity or disease prevention.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
Explore 4 sourced accounts by reported effect.
Energy: reported experiences
Sharper thinking with initial tiredness
A 28-year-old reported feeling mentally sharper and less depressed after a brief exposure, with tiredness on the first day that then passed.
Reported use in this account
- Product
- Fisetin capsules; formulation not otherwise verified
- Amount
- 2 grams per day, also described as 20 mg/kg/day
- Frequency
- Daily
- Route
- Not specified clearly
- Duration
- Two days
The author acknowledged a possible placebo effect. Promised laboratory follow-up was not visible; this does not establish senescent-cell removal or depression treatment.
Read the original accountFeeling overstimulated and unable to sleep
Another commenter reported feeling unusually activated and having insomnia on both nights of a short exposure, while also drinking coffee.
Reported use in this account
- Product
- Product described as fisetin
- Amount
- 1.2 grams
- Frequency
- Daily
- Route
- Not specified clearly
- Duration
- Two days
Other exposures described: Coffee
Caffeine and other influences were not controlled. The proposed explanation in the thread was speculation.
Read the original accountSleep: reported experiences
Feeling overstimulated and unable to sleep
Another commenter reported feeling unusually activated and having insomnia on both nights of a short exposure, while also drinking coffee.
Reported use in this account
- Product
- Product described as fisetin
- Amount
- 1.2 grams
- Frequency
- Daily
- Route
- Not specified clearly
- Duration
- Two days
Other exposures described: Coffee
Caffeine and other influences were not controlled. The proposed explanation in the thread was speculation.
Read the original accountMood: reported experiences
Sharper thinking with initial tiredness
A 28-year-old reported feeling mentally sharper and less depressed after a brief exposure, with tiredness on the first day that then passed.
Reported use in this account
- Product
- Fisetin capsules; formulation not otherwise verified
- Amount
- 2 grams per day, also described as 20 mg/kg/day
- Frequency
- Daily
- Route
- Not specified clearly
- Duration
- Two days
The author acknowledged a possible placebo effect. Promised laboratory follow-up was not visible; this does not establish senescent-cell removal or depression treatment.
Read the original accountFocus: reported experiences
Sharper thinking with initial tiredness
A 28-year-old reported feeling mentally sharper and less depressed after a brief exposure, with tiredness on the first day that then passed.
Reported use in this account
- Product
- Fisetin capsules; formulation not otherwise verified
- Amount
- 2 grams per day, also described as 20 mg/kg/day
- Frequency
- Daily
- Route
- Not specified clearly
- Duration
- Two days
The author acknowledged a possible placebo effect. Promised laboratory follow-up was not visible; this does not establish senescent-cell removal or depression treatment.
Read the original accountPain: reported experiences
Less pain with stomach upset
A person describing lupus reported a reduction in musculoskeletal pain after bio-fisetin, alongside gastrointestinal upset. A later reply described continued exposure without a systematic symptom record.
Reported use in this account
- Product
- Products called Bio-Fisetin and regular fisetin powder
- Amount
- One Bio-Fisetin pill; strength not stated
- Frequency
- Bio-Fisetin once weekly in a later reply; powder a few times weekly
- Route
- Not specified clearly
- Duration
- Not specified clearly
Other exposures described: Regular fisetin powder, amount not quantified; magnesium and other unspecified medicines/supplements
Other medicines and supplements, including magnesium, were involved. The formulation and individual outcome were not verified; this is not evidence of lupus treatment.
Read the original accountDigestion: reported experiences
Less pain with stomach upset
A person describing lupus reported a reduction in musculoskeletal pain after bio-fisetin, alongside gastrointestinal upset. A later reply described continued exposure without a systematic symptom record.
Reported use in this account
- Product
- Products called Bio-Fisetin and regular fisetin powder
- Amount
- One Bio-Fisetin pill; strength not stated
- Frequency
- Bio-Fisetin once weekly in a later reply; powder a few times weekly
- Route
- Not specified clearly
- Duration
- Not specified clearly
Other exposures described: Regular fisetin powder, amount not quantified; magnesium and other unspecified medicines/supplements
Other medicines and supplements, including magnesium, were involved. The formulation and individual outcome were not verified; this is not evidence of lupus treatment.
Read the original accountNo clear change: reported experiences
No noticeable change
A separate commenter described repeated intermittent fisetin exposure over several months without a noticeable effect.
Reported use in this account
- Product
- Product described as fisetin
- Amount
- 800 mg on two described days and 700 mg on two other described days
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- A four-day exposure was described
No baseline measurements or controlled comparison were provided. Lack of a felt effect cannot establish biological inactivity.
Read the original accountApproval status
Fisetin is being studied in human trials but has no FDA-approved drug use for senescence, frailty, cardiovascular aging, cancer recovery, or longevity. Supplement products are not FDA approved for effectiveness.
Small human senolytic trials
Fisetin has a small Phase 2 frailty trial record and early human mechanistic research, but no FDA-approved senolytic, frailty, or longevity indication.
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Whether fisetin reliably clears clinically relevant senescent cells in people
- Whether biomarker effects improve function, disease risk, or survival
- Which tissues and populations could benefit or be harmed
- Long-term safety and interactions
Summary
Fisetin is one of the better-known experimental senolytics, but its reputation still rests mainly on preclinical work. Human longevity benefit has not been shown.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- pubmedPreclinical fisetin healthspan and lifespan study
Cell, tissue, and mouse evidence that motivated human senolytic research.
- clinical trialsClinicalTrials.gov: AFFIRM-LITE
Small Phase 2 frailty trial record with no public outcomes result.
- pubmedEarly human fisetin vascular-aging study
Mechanistic human study that does not establish longevity or disease prevention.
- fdaFDA: dietary supplements are not preapproved for effectiveness
FDA explanation of the regulatory distinction between approved drugs and marketed dietary supplements.